Please login to the form below
CHB
This page shows the latest CHB news and features for those working in and with pharma, biotech and healthcare.
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
Around 260 million people worldwide are currently living with CHB compared to around 70 million with hepatitis C. ... GSK3228836 uses antisense oligonucleotide technology to suppress the virus and viral proteins to functionally cure CHB.
Latest news
-
GSK to develop Ionis hepatitis B drugs
GlaxoSmithKline has exercised its option to license Ionis' antisense medicines for chronic hepatitis B virus (CHB) infection, boosting its presence in virology. ... cancer. Current treatments for patients with CHB provide low levels of hepatitis B virus
-
CHMP recommends Teva's generic version of Astellas' Advagraf
Hepatitis B drug Pegasys has now been recommended to treat non-cirrhotic paediatric patients who are HBeAg-positive CHB with evidence of viral replication and persistently elevated serum ALT levels.
-
Dr Jeffrie R Strang: If I could change one thing…
Dr Jeffrie R Strang MB ChB MPH (Harvard) FFPH, Associate Medical Director, Visions4health.
-
Gamification in pharma
The Masterminds in CHB quiz. . The idea was gamification at its most basic: appeal to the competitive spirit.
Dr Jeffrie R Strang: If I could change one thing…
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
